Recently, assays to investigate immuno checkpoint protein interactions in relation to immunotherapy drug discovery programs have been added to the portfolio of products and services (e.g. PD-1/PD-L1/PD-L2; B7-1/CD28, B7-1/CTLA4; BLTA/HVEM, CD47/SIRPα; GITR/GITRL; CD47:SIRPα; CD137:CD137L; CD40:CD40L; TIGIT/CD226 as well as the Trp catabolism pathway (IDO and TDO)).
Their expanding offer is available in Europe via tebu-bio. For advice on choosing your BPS products, get in touch with your local tebu-bio office.
Find your BPS Bioscience's products below or contact your tebu-bio local office.
Split per categoryPrimary Antibodies Cell Based Assays Functional Assays Media & ECM Cell Lines Enzymes Cloning Tools Buffers Lipids Inhibitors & Activators Chemicals Labelling Substrates Peptides Proteins
Immunotherapy Screening A focus on PD-1/PD-L1/PD-L2 Pathway in drug discovery Facebook Google+ Linkedin Twitter YouTube
Proteins with the High Purity (HiPTM) label make the difference Facebook Google+ Linkedin Twitter YouTube
Versatile method to detect luciferase in reporter cell lines Facebook Google+ Linkedin Twitter YouTube
New Continued use immunotherapy cell line expressing recombinant PD-1 Facebook Google+ Linkedin Twitter YouTube
Immunotherapy Screening B7-1 / CD28 and B7-1 / CTLA4 Pathways in Drug Discovery Facebook Google+ Linkedin Twitter YouTube